As of November 7, 2026, Allogene Therapeutics, Inc is a publicly traded company (Nasdaq: ALLO). The largest holder reporting an active stake on Schedule 13D is Pfizer Inc., at 9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (6.7%), Frazier Life Sciences Public Fund, L.P. (5.6%), State Street (5.5%) (Schedule 13D/A, February 13, 2026).
Is this your company?
About to sign with, pay or invest in Allogene Therapeutics, Inc? See the free Snapshot first.
Free to see. No signup.
Is Allogene Therapeutics, Inc a real, registered company?
- Allogene Therapeutics, Inc files with the SEC under CIK 1737287 (its SEC filings).
- Its shares are listed under the ticker ALLO on Nasdaq (SEC company record).
- business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Allogene Therapeutics, Inc in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Allogene Therapeutics, Inc's owners and officers?
Allogene Therapeutics, Inc: business address in South San Francisco, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 6.7% |
| Schedule 13D/A, 2026-09-30 | Tpg Gp A, LLC | 0% |
| Schedule 13G/A, 2026-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.6% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.5% |
| Schedule 13G/A, 2026-08-07 | Arie Belldegrun, M.D. | 3.9% |
| Schedule 13G/A, 2026-05-15 | Lynx1 Capital Management LP | 0% |
| Schedule 13G/A, 2026-05-15 | Kenneth Griffin | 2.8% |
| Schedule 13G/A, 2026-05-13 | David D. Chang, M.D., Ph.D. | 4.9% |
| Schedule 13G/A, 2026-05-13 | Arie Belldegrun, M.D. | 5.4% |
| Schedule 13G, 2026-04-23 | Frazier Life Sciences Public Fund, L.P. | 4.7% |
| Schedule 13G/A, 2026-02-17 | Arie Belldegrun, M.D. | 5.8% |
| Schedule 13D/A, 2026-02-13 | Pfizer Inc. | 9% |
Questions about who owns Allogene Therapeutics, Inc
Who owns Allogene Therapeutics, Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Allogene Therapeutics, Inc: Pfizer Inc. (9%, Schedule 13D/A, filed 2026-02-13), Blackrock, Inc. (6.7%, Schedule 13G/A, filed 2026-10-27), Frazier Life Sciences Public Fund, L.P. (5.6%, Schedule 13G/A, filed 2026-08-14) and State Street Corporation (5.5%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Allogene Therapeutics, Inc?
By the share each holder's latest filing reports, the largest holders of Allogene Therapeutics, Inc on this page are Pfizer Inc. (9%), Blackrock, Inc. (6.7%) and Frazier Life Sciences Public Fund, L.P. (5.6%).
When did Pfizer Inc. buy into Allogene Therapeutics, Inc?
The filings give report dates, not purchase dates. The earliest filing from Pfizer Inc. on this page is the Schedule 13D/A, filed 2026-02-13, reporting 9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Allogene Therapeutics, Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Allogene Therapeutics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Allogene Therapeutics, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Allogene Therapeutics, Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 6,351,707 shares (1.8% of shares outstanding), 5,150,599 held directly and 1,201,108 indirectly (Form 4, 2026-03-18).
- , a director: 2,776,683 shares (0.80% of shares outstanding), 2,236,816 held directly and 539,867 indirectly (Form 4, 2026-02-04).
- , the chief financial officer: 1,045,877 shares (0.30% of shares outstanding) (Form 4, 2026-10-23).
- , the executive vice president of r and d: 581,166 shares (0.17% of shares outstanding) (Form 4, 2026-02-04).
- , the general counsel and senior vice president: 488,267 shares (0.14% of shares outstanding) (Form 4, 2026-08-25).
Shares outstanding: 346,467,307 as of 2026-11-03, from the company's latest SEC cover page.
How much has Allogene Therapeutics, Inc raised?
No fundraising or offering filing from Allogene Therapeutics, Inc is on file with us.
Keep reading
More on Allogene Therapeutics, Inc and the records around it.
Allogene Therapeutics, Inc elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Pfizer Inc. also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), NEXTCURE, INC. (Feb 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- TPG GP A, LLC also filed stake reports on 15 other companies: TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026), LifeStance Health Group, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/allogene-therapeutics